- Home
- ACB vs ALEC Comparison
ACB vs ALEC Comparison
Compare ACB & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | ALEC |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3M | 262.7M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACB | ALEC |
|---|---|---|
| Price | $3.68 | $2.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 587.5K | ★ 625.5K |
| Earning Date | 02-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $6.31 | $18.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.07 | $0.90 |
| 52 Week High | $6.67 | $3.40 |
Technical Indicators
Market Signals| Indicator | ACB | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 62.00 |
| Support Level | $3.28 | $1.89 |
| Resistance Level | $3.91 | $2.57 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 97.71 | 89.78 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.